September 26, 2021
  • September 26, 2021
  • Home
  • Eye diseases
  • Stealth BioTherapeutics to Present at HC Wainwright Ophthalmic Healthcare Virtual Conference

Stealth BioTherapeutics to Present at HC Wainwright Ophthalmic Healthcare Virtual Conference

By on August 11, 2021 0

BOSTON, August 11, 2021 / PRNewswire / – Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie mccarthy, CEO, will present at the HC Wainwright Ophthalmology Virtual Conference on Tuesday August 17, 2021 To 7:00 a.m.ET. In addition, Stealth management will also participate in HC Wainwright’s “Addressing Unmet Medical Needs in Macular Degeneration – Dry AMD and Stargardt Disease” panel at the event on August 17, 2021 To 11:00 a.m.ET.

Stealth BioTherapeutics Logo (PRNewsFoto / Stealth BioTherapeutics) (PRNewsfoto / Stealth BioTherapeutics)

A live audio webcast of the presentation will be available in the Investors & News section of the Stealth website at https://investor.stealthbt.com/. A replay of the webcast will be archived on the Stealth website for 30 days after the event.

About stealth
We are a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in almost every cell in the body, are the body’s main source of energy production and are essential for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are implicated in many common age-related diseases, typically involving energy-intensive organ systems such as the heart, eyes, and brain. We believe that our lead product candidate, elamipretid, has the potential to treat both rare metabolic cardiomyopathies, such as Barth muscular dystrophy, Duchenne muscular dystrophy and Friedreich’s ataxia, rare mitochondrial diseases resulting in mutations of nuclear DNA, as well as ophthalmic diseases resulting in mitochondrial dysfunction, such as dry age-related macular degeneration and Leber’s hereditary optic neuropathy. We are evaluating our second generation clinical stage candidate, SBT-272, and our new small molecule series, SBT-550, for indications of rare neurological diseases following promising preclinical data. We have optimized our discovery platform to identify novel mitochondria-targeted compounds that can be named as therapeutic product candidates or used as mitochondria-targeted vectors to deliver other compounds to mitochondria.

Investor Relations
Serious investor relations
Janhavi Mohite, 212-362-1200
[email protected]

Cision

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-present-at-hc-wainwright-ophthalmology-virtual-healthcare-conference-301352781.html

SOURCE Stealth BioTherapeutics Inc.


Source link